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Abstract 
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Bone-forming osteoblasts are differentiated from mesenchymal stem cells and 
dysregulation of this differentiation can lead to osteoporosis. Meanwhile, 
bone-resorbing osteoclasts are both differentiated and multinucleated from 
hematopoietic precursor cells of monocyte and/or macrophage lineage. Bone resorption 
inhibitors such as bisphosphonates and estrogen are used to treat osteoporosis. However, 
the adverse effects of the long-term use of these medicines are of concern. Therefore, 
the development of new therapies to ameliorate osteoporosis is desired. Therefore, in 
the present study, we screened 22 plant extracts and found that nine methanolic extracts 
of medicinal plants promote the differentiation of MC3T3-E1 cells to osteoblasts. These 
nine extracts were then evaluated for their inhibitory activity on osteoclast 
differentiation in RAW264.7 mouse macrophage cells. Among the nine extracts, Daucus 
carota, Vitis spp., Sasa veitchii, Euptelea polyandra, and Sesamum indicum exhibited 
pro-osteoblastic and anti-osteoclastic activity with low cytotoxicity, suggesting their 
potential effectiveness against osteoporosis. 
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Introduction 
Osteoporosis is a condition characterized by a decrease in bone density and strength, 
resulting in fragile bones [1]. Normal bone is dependent on the balance of bone 
formation and resorption. Postmenopausal osteoporosis is a common bone disease in 
elderly women. Estrogen deficiency is known to increase bone turnover, leading to 
osteoclastic bone resorption [2]. For treatment against osteoporosis, bone resorption 
inhibitors, such as bisphosphonate, calcitonin, and estrogen, and bone formation 
promoters, such as parathyroid hormone, are used in the clinical setting. However, the 
adverse effects resulting from the long-term use of these medicines are of concern. For 
example, estrogen may increase the risk of breast and endometrial cancers [3]. 
Therefore, the development of alternative medicines against osteoporosis is desired. 
In the present study, we screened 22 medicinal plant extracts for the promotion of 
osteoblast differentiation and mineralization in the osteoblastic cell line MC3T3-E1 and 
the inhibition of osteoclast differentiation in RAW264.7 mouse macrophage cells. 
 
Materials and methods 
Materials 
Odontioda Marie Noel ‘Velano’ (leaf: 1, bulb: 2, root: 3), Odontoglossum Harvengtense 
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‘tutu’ (leaf: 4, bulb: 5, root: 6), Pandanus amaryllifolius (7), Daucus carota (8), Myrica 
rubra (twig: 9, leaf: 10), Vitis spp. (11), Camptotheca acuminata (12), Rhinacanthus 
nasutus (13), Sasa veitchii (14), Euptelea polyandra (15), Nandina domestica (16), 
Theobroma cacao (17), Phellodendron amurense (18), Sophora flavescens (cultivated in 
Hangzhou: 19, cultivated in Beijing: 21), Actinidia polygama (20), Sesamum indicum 
(22) were used in this study (Table 1). Voucher specimens were deposited in the 
Laboratory of Pharmacognosy and Natural Medicines. 
 
Preparation of extracts 
Dried samples were extracted with methanol in reflux for an hour three times to give the 
corresponding extract. These extracts were then evaporated to remove the organic 
solvent. The resulting extracts were stored at –20°C before use. 
 
Cell culture and osteoblast differentiation 
Osteoblastic MC3T3-E1 cells (mouse calvarial origin) were grown in α-minimal 
essential medium (α-MEM; Wako Pure Chemical Industries, Osaka, Japan) containing 
10% fetal bovine serum (FBS; Thermo, Melbourne, Australia), 100 U/mL penicillin, 
and 100 µg/mL streptomycin (Gibco BRL, New York, NY, USA) at 37°C in a 
5 
 
humidified atmosphere of 5% CO2 in air. 
For osteoblast differentiation, after the cells were grown to confluence, the culture 
medium was changed to an osteogenic medium containing 100 µg/mL ascorbic acid and 
100 mM β-glycerophosphate (defined as differentiation medium) with or without 
samples. The medium was changed every 3 days. The differentiation of osteoblasts was 
evaluated based on staining alkaline phosphatase (ALP) activity. Cells were then rinsed 
and fixed with 4% paraformaldehyde. After treatment with ethanol/acetone (1:1) 
mixture, ALP activity in the cells was stained using 5-bromo-4-chloro-3-indolyl 
phosphate and nitroblue tetrazolium in 0.5 M Tris buffered saline (pH 9.5). To quantify 
the ALP staining intensity, stained cells were dissolved in solvent containing 10% 
sodium dodecyl sulfate (SDS), 50% N, N-dimethylformamide (DMF) and 10% acetic 
acid, and measured at 540 nm using a microplate reader. 
 
Cell viability 
Cell proliferation and cytotoxicity were determined by 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. First, 1 
mg/mL MTT solution was added to the cells and incubated for 2 h. After removal of the 
culture supernatants, formazan crystals were dissolved in isopropanol: dimethyl 
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sulfoxide (DMSO) (1:1) solution. Absorbance was measured at 595 nm using a 
microplate reader. 
 
Mineralization assay 
Mineral depositions of osteoblasts were measured using Alizarin red S (Cosmo Bio, 
Tokyo, Japan) and von Kossa staining (Wako Pure Chemical Industries, Osaka, Japan). 
At the end of culture, cells were fixed with 4% paraformaldehyde and stained with 40 
mM Alizarin red S (pH 6.4) for 10 min. Fixed cells were also stained with von Kossa 
according to the manufacturer’s instructions. Stained cells were then visualized using 
light microscopy and photographed. 
 
Assay for osteoclast differentiation 
Osteoclasts were differentiated from RAW264.7 mouse macrophage cells as described 
previously [4]. Briefly, cells were cultured with α-MEM containing 10% FBS on 
96-well plates. For osteoclast differentiation, the cells were cultured in the presence of 
the receptor activator of NFκB ligand (RANKL, 10 ng/mL; R & D Systems, 
Minneapolis, MN, USA) with or without test samples for 4 days. Next, the 
tartrate-resistant acid phosphatase (TRAP) activity of the medium was measured and 
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TRAP staining was performed. 
 
Measurement of TRAP activity and TRAP staining 
The TRAP activity of osteoclasts was measured with culture media (30 µL) incubated 
for 20 min at 37°C with 30 µL of 600 mM sodium acetate buffer (pH 5.5) containing 
L-ascorbic acid (17.6 mg/mL), sodium tartrate dehydrate (9.2 mg/mL), 
4-nitrophenylphosphate Na (3.6 mg/mL), Triton X-100 (0.3%), 
ethylenediaminetetraacetic acid (EDTA) (6 mM), and NaCl (600 mM). The reaction was 
terminated by the addition of 30 µL of NaOH (300 mM), and then the absorbance was 
measured at 405 nm. TRAP histochemical staining of the cells was performed using a 
leukocyte acid phosphatase kit (Sigma-Aldrich, St. Louis, MO, USA). Cultured cells 
were fixed with 100% methanol for 1 min at room temperature and air-dried. TRAP 
staining was performed according to the manufacturer’s instructions. TRAP-positive 
multinucleated (more than three nuclei) cells were photographed under inverted 
phase-contrast microscopy [5]. 
 
Statistical analysis 
The data are presented as mean±standard deviation of at least three independent 
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experiments. Statistical analysis was performed using the Student’s t-test. In all analyses, 
P<0.05 was taken to indicate statistical significance. 
 
Results and discussion 
In the present study, we screened 22 medicinal plant extracts for the promotion of 
osteoblast differentiation and mineralization in MC3T3-E1 cells. Treatment with D. 
carota (leaf) (8), S. veitchii (leaf) (14), and S. flavescens (Beijing) (21) extracts more 
than doubled ALP activity compared with the control. O. Harvengtense ‘Tutu’ (leaf) (4), 
M. rubra (twig) (9), M. rubra (leaf) (10), V. spp. (root) (11), R. nasutus (leaf) (13), E. 
polyandra (leaf) (15), and S. indicum (leaf) (22) enhanced ALP activity more than 1.5 
times more than the control in a dose-dependent manner (Fig. 1a). No stimulation of 
cell proliferation and cytotoxicity was observed except for M. rubra (twig) (9) and M. 
rubra (leaf) (10), and high doses of O. Marie Noel ‘Velano’ (leaf) (1), O. Harvengtense 
‘tutu’ (leaf) (4), E. polyandra (15), and S. flavescens (Beijing) (21) (Fig. 1b). O. Marie 
Noel ‘Velano’ (bulb) (2), O. Marie Noel ‘Velano’ (root) (3), O. Harvengtense ‘Tutu’ 
(root) (6), C. acuminata (leaf) (12), and N. domestica (leaf) (16) decreased ALP and 
MTT activity at concentrations of 50 µg/mL (Fig. 1a). However, these extracts did not 
enhance ALP activity at any concentration, including less than 5 µg/mL (data not 
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shown). Treatment with a higher concentration (100 µg/mL) of the 17 other extracts, 
except S. flavescens (Hangzhou) (19), showed decreased ALP activity compared with 50 
µg/mL (data not shown). Next, based on the results of the first screening, nine medicinal 
plant extracts (O. Harvengtense ‘Tutu’ (leaf), D. carota (leaf), M. rubra (twig), M. rubra 
(leaf), V. spp. (root), S. veitchii (leaf), E. polyandra (leaf), S. flavescens (root), and S. 
indicum (leaf)) were selected to further confirm the dose-dependent effect on the 
enhancement of ALP activity. All samples dose-dependently increased ALP activity, 
reaching the maximum in the range of 25–100 µg/mL (Fig. 2a). O. Harvengtense ‘Tutu’ 
(leaf) (4) and E. polyandra (leaf) (15) inhibited both ALP and MTT activity at a 
concentration of 100 µg/mL (Fig. 2b). All other extracts except M. rubra (leaf) (10) 
increased ALP activity without inducing cytotoxicity. 
Next, the selected plant extracts were evaluated for mineralization activities using 
Alizarin red S and von Kossa staining (Fig. 3). Calcium deposition was not detected in 
undifferentiated MC3T3-E1 cells, whereas it was detected in the cells cultured in 
osteogenic medium for 2 weeks. Treatment of 50 µg/mL of these plant extracts except S. 
flavescens (root) further promoted calcium deposition as evaluated by Alizarin red S 
staining (Fig. 3). Among these extracts, M. rubra (twig) (9), M. rubra (leaf) (10), S. 
veitchii (leaf) (14), and S. indicum (leaf) (22) promoted marked mineralization of 
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MC3T3 cells compared with bone morphogenetic protein (BMP). After 3 weeks in 
culture, mineralization of MC3T3 cells treated with all nine medicinal plant extracts 
described above was observed by von Kossa staining. 
We also investigated whether these nine medicinal plant extracts could inhibit 
RANKL-stimulated osteoclast formation from RAW264.7 cells. As shown in Fig. 4a, all 
plant extracts except S. flavescens (Hangzhou) (19) dose-dependently inhibited 
RANKL-induced TRAP activity. S. flavescens (Hangzhou) (19) had little effect on 
RANKL-induced TRAP activity. It should be noted that Vitis spp. (root) (11) inhibited 
TRAP activity without inducing cytotoxicity (Fig. 4b). Although D. carota (leaf) (8) and 
S. indicum (leaf) (22) induced mild cytotoxicity, these extracts inhibited TRAP activity. 
TRAP-positive multinucleated giant cells were observed in the culture treated with 
RANKL, while treatment with all extracts except S. flavescens (Hangzhou) (19) 
dose-dependently inhibited RANKL-stimulated multinucleated cell formation in 
varying degrees (Fig. 5). In addition, 100 µg/mL of O. Harvengtense ‘Tutu’ (leaf) (4), S. 
veitchii (leaf) (14), and E. polyandra (leaf) (15) completely inhibited RANKL-induced 
multinucleated mature osteoclasts. 
 
Conclusions 
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In the present study, we screened 22 medicinal plant extracts for the promotion of 
osteoblast differentiation and mineralization in MC3T3-E1 cells. Nine extracts showed 
enhanced ALP activity and mineralization in MC3T3-E1 cells. Furthermore, the 
inhibitory effects of these candidates on osteoclast differentiation were evaluated. The 
results suggest that D. carota (8), V. spp. (11), S. veitchii (leaf) (14), E. polyandra (15), 
and S. indicum (22) have potential as effective medicinal plant extracts against 
osteoporosis because they promote osteoblast differentiation while inhibiting osteoclast 
differentiation without cell damage. In a future study, we plan to identify the active 
components of these medicinal plants and clarify their underlying mechanisms. 
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Figure legends 
Fig. 1 ALP activity in MC3T3-E1 cells treated with various medical plant extracts. (a) 
MC3T3-E1 cells were cultured either in undifferentiated media or in differentiated 
media untreated (control) or treated with the indicated concentration of plant extracts for 
4 days. Cells were stained for ALP activity, solubilized, and then measured for 
absorbance. The ALP activities are expressed as a ratio to control culture. (b) Cell 
toxicity of MC3T3-E1 cells was evaluated by MTT assay. Cells were cultured as shown 
in Fig 1a. MTT assay was performed as described in the “Materials and Methods”. Cell 
viabilities are expressed as a ratio to control culture. Each column represents the 
mean±SD of three independent experiments. *P<0.05 vs. control. 
 
Fig. 2 ALP activity in MC3T3-E1 cells treated with selected medical plant extracts. (a) 
MC3T3-E1 cells were cultured as shown in Fig. 1a with or without selected medical 
plant extracts. ALP activities are expressed as a ratio to control culture. (b) Cell toxicity 
of MC3T3-E1 cells was evaluated by MTT assay as shown in Fig. 1b. Each column 
represents the mean±SD of three independent experiments. *P<0.05 vs. control. 
 
Fig. 3 Mineral deposition in MC3T3-E1 cells treated with selected medical plant 
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extracts. MC3T3-E1 cells were cultured as shown in Fig. 1a for the indicated times. The 
cells were stained with Alizarin red S and von Kossa to measure mineral deposition. 
BMP was used as a positive control for osteoblast differentiation. 
 
Fig. 4 TRAP activity in RAW264.7 cells treated with selected medical plant extracts. (a) 
RAW264.7 cells were cultured in either undifferentiated media or RANKL-treated 
differentiated media without (control) or with selected medical plant extracts for 4 days. 
TRAP activity in the culture medium was measured (a) and MTT assay (b) was 
performed, as described in the “Materials and Methods”. Each column represents the 
mean±SD from three independent experiments. *P<0.05 vs. control. 
 
Fig. 5 TRAP-positive multinucleated cell formation from RAW264.7 cells treated with 
selected medical plant extracts. RAW264.7 cells were cultured as shown in Fig. 4. Cells 
were stained for TRAP activity as described in the “Materials and Methods”. 
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